Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation

Core Insights - Cardinal Health has raised its fiscal year 2026 non-GAAP diluted EPS outlook to at least $10.00, up from the previous range of $9.65 to $9.85, reflecting strong performance across its operating segments [3][9] - The company anticipates Specialty revenues to exceed $50 billion in fiscal year 2026, representing a 16% compound annual growth rate (CAGR) over three years [4][9] - Cardinal Health has successfully transitioned its manufacturer distribution service agreements in response to the 2026 Medicare Drug Price Negotiation Program changes [7][9] Financial Outlook - The updated non-GAAP diluted EPS for fiscal year 2026 is projected to be at least $10.00, indicating a positive trend in the company's financial performance [3][9] - The increase in EPS expectations is attributed to effective execution of the company's strategic growth plan across its five operating segments [2][3] Specialty Growth - Cardinal Health expects Specialty revenues to surpass $50 billion in fiscal year 2026, driven by strong demand in specialty distribution and a projected 30% revenue growth in BioPharma Solutions [4][9] - The BioPharma Solutions segment has seen significant wins, including partnerships with leading manufacturers for patient support programs, serving over 1 million patients [5][9] Strategic Initiatives - The company introduced the ContinuCare™ Pathway program to simplify diabetes supply management for pharmacies and patients, enhancing access to diabetes supplies [10][11] - Publix Super Markets Inc. has enrolled its entire pharmacy network in the ContinuCare™ Pathway program, expanding its reach to over 11,000 retail and grocery pharmacies [12][9] Investor Engagement - Cardinal Health will present at the J.P. Morgan Healthcare Conference, providing further insights into its strategic initiatives and financial outlook [13]